ArticleThe Journal of infectious diseases2015
Stat1-Deficient Mice Are Not an Appropriate Model for Efficacy Testing of Recombinant Vesicular Stomatitis Virus-Based Filovirus Vaccines.
Article in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- A lethal mice model of recombinant vesicular stomatitis viruses for EBOV-targeting prophylactic vaccines evaluation.Virologica Sinica · 2024Article
- Establishment of two serological methods for detecting IgG and neutralizing antibodies against Crimean-Congo hemorrhagic fever virus glycoprotein.Frontiers in cellular and infection microbiology · 2024Article
- YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge.NPJ vaccines · 2023Article
- Immunocompromised Cas9 transgenic mice for rapidMolecular therapy. Methods & clinical development · 2021Article
- Physiopathology and effectiveness of therapeutic vaccines against human papillomavirus.Environmental science and pollution research international · 2021Review
- Article
- Article
- Article
- Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors.Journal of virology · 2020Article
- The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies.Antiviral research · 2020Review
- Marburg virus pathogenesis - differences and similarities in humans and animal models.Virology journal · 2019Review
- Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge.EBioMedicine · 2019Article
- Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever.Scientific reports · 2019Article
- Filovirus Virulence in Interferon α/β and γ Double Knockout Mice, and Treatment with Favipiravir.Viruses · 2019Article
- Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.Nature communications · 2018Article
- Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.Human gene therapy · 2018Article
- A VSV-based Zika virus vaccine protects mice from lethal challenge.Scientific reports · 2018Article
- Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation.Frontiers in immunology · 2018Article
- Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.The Journal of infectious diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Stat1(-/-) mice lack a response to interferon α, β, and γ, allowing for replication of nonadapted wild-type (wt) Ebolavirus and Marburgvirus. We sought to establish a mouse model for efficacy testing of live attenuated recombinant vesicular stomatitis virus (rVSV)-based filovirus vaccine vectors using wt Ebolavirus and Marburgvirus challenge strains. While infection of immunocompetent mice with different rVSV-based filovirus vectors did not cause disease, infection of Stat1(-/-) mice with the same vectors resulted in systemic infection and lethal outcome for the majority of tested rVSVs. Despite differences in viral loads, organ tropism was remarkably similar between rVSV filovirus vaccine vectors and rVSVwt, with the exception of the brain. In conclusion, Stat1(-/-) mice are not an appropriate immunocompromised mouse model for efficacy testing of live attenuated, replication-competent rVSV vaccine vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.